N‐methyl‐D‐aspartate antagonists: Ready for clinical trial in brain ischemia?

G. W. Albers; M. P. Goldberg; D. W. Choi

doi:10.1002/ana.410250412

N‐methyl‐D‐aspartate antagonists: Ready for clinical trial in brain ischemia?

G. W. Albers, M. P. Goldberg, D. W. Choi

Research output: Contribution to journal › Review article › peer-review

235 Scopus citations

Abstract

Antagonists of the N‐methyl‐D‐aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well‐developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK‐801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.

Original language	English (US)
Pages (from-to)	398-403
Number of pages	6
Journal	Annals of Neurology
Volume	25
Issue number	4
DOIs	https://doi.org/10.1002/ana.410250412
State	Published - Apr 1989

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1002/ana.410250412

Cite this

@article{7d057e8095214ac8bc7b33fc29980dc6,

title = "N‐methyl‐D‐aspartate antagonists: Ready for clinical trial in brain ischemia?",

abstract = "Antagonists of the N‐methyl‐D‐aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well‐developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK‐801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.",

author = "Albers, {G. W.} and Goldberg, {M. P.} and Choi, {D. W.}",

year = "1989",

month = apr,

doi = "10.1002/ana.410250412",

language = "English (US)",

volume = "25",

pages = "398--403",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - N‐methyl‐D‐aspartate antagonists

T2 - Ready for clinical trial in brain ischemia?

AU - Albers, G. W.

AU - Goldberg, M. P.

AU - Choi, D. W.

PY - 1989/4

Y1 - 1989/4

N2 - Antagonists of the N‐methyl‐D‐aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well‐developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK‐801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.

AB - Antagonists of the N‐methyl‐D‐aspartate (NMDA) subclass of glutamate receptors may offer a new approach for the treatment of ischemic brain injury. This strategy is supported by a well‐developed scientific foundation and encouraging results in a variety of in vivo and in vitro experimental models. Several specific antagonists, including MK‐801, dextrorphan, dextromethorphan, and ketamine, have already been used at low doses in humans for other indications and are potential candidates for Phase I clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0024559799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024559799&partnerID=8YFLogxK

U2 - 10.1002/ana.410250412

DO - 10.1002/ana.410250412

M3 - Review article

C2 - 2565699

AN - SCOPUS:0024559799

SN - 0364-5134

VL - 25

SP - 398

EP - 403

JO - Annals of Neurology

JF - Annals of Neurology

IS - 4

ER -

N‐methyl‐D‐aspartate antagonists: Ready for clinical trial in brain ischemia?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this